B9P0 Stock Overview
Develops and sells eyecare and wound care products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NovaBay Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.80 |
| 52 Week High | US$5.67 |
| 52 Week Low | US$2.27 |
| Beta | 0.83 |
| 11 Month Change | 0% |
| 3 Month Change | -34.96% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| B9P0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -0.2% |
| 1Y | n/a | -22.4% | 7.8% |
Return vs Industry: Insufficient data to determine how B9P0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how B9P0 performed against the German Market.
Price Volatility
| B9P0 volatility | |
|---|---|
| B9P0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B9P0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine B9P0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25 | Justin Hall | novabay.com |
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
NovaBay Pharmaceuticals, Inc. Fundamentals Summary
| B9P0 fundamental statistics | |
|---|---|
| Market cap | €2.26m |
| Earnings (TTM) | -€14.94m |
| Revenue (TTM) | €12.43m |
0.2x
P/S Ratio-0.2x
P/E RatioIs B9P0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B9P0 income statement (TTM) | |
|---|---|
| Revenue | US$13.88m |
| Cost of Revenue | US$5.94m |
| Gross Profit | US$7.94m |
| Other Expenses | US$24.63m |
| Earnings | -US$16.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.41 |
| Gross Margin | 57.20% |
| Net Profit Margin | -120.16% |
| Debt/Equity Ratio | -112.8% |
How did B9P0 perform over the long term?
See historical performance and comparison